ArticlePediatric nephrology (Berlin, Germany)2025
Telitacicept use in children with IgA vasculitis nephritis: preliminary observations.
Article in Pediatric nephrology (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07354503 (The Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Vasculitis-Associated Nephritis), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Vasculitis-Associated Nephritis: A Multicenter Clinical Study
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immune-mediated renal injury and cardiometabolic risk in IgA nephropathy: clinical evidence on telitacicept from a scoping review.Frontiers in nutrition · 2026Pooled it
- [Preliminary evaluation of the efficacy and safety of telitacicept in children with IgA nephropathy].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- [Research progress on the application of telitacicept in rheumatism and autoimmune diseases].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Review
- Short-term changes in clinical parameters associated with telitacicept in pediatric IgA nephropathy: a single-center self-controlled observational study.Frontiers in pediatrics · 2026Article
- Efficacy and safety of telitacicept in children with IgA vasculitis and IgA vasculitis nephritis: a single-center retrospective study.Pediatric rheumatology online journal · 2025Observational
- Efficacy and Safety of Telitacicept in IgA Nephropathy and IgA Vasculitis-Associated Nephritis in Children: A Retrospective Single-Centre Study.Drug design, development and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesTo investigate the safety and efficacy of telitacicept in children with immunoglobulin (Ig) A vasculitis nephritis (IgAVN).
methodsThis is a case series of children with biopsy-confirmed IgAVN who received glucocorticoid with or without a second immunosuppressant and presented with urinary protein levels > 0.3 g/day/kg. The patients were administered telitacicept subcutaneously weekly as an adjunct to the standard treatment. The laboratory indices were assessed before and 24 weeks post-treatment, and the treatment's efficacy and side effects were analyzed.
resultsSeven patients (six males and one female) were enrolled in the study. The median age and body weight of patients were 13 years and 48 kg, respectively. The median disease duration was 29 months. After treatment with telitacicept (80 or 160 mg administered per week) until the 24th week, the 24-h urinary protein levels, percentage of CD19 + B cells, and IgA and IgM levels were decreased compared to the baseline values (P < 0.05). Serum albumin and complement C4 levels increased significantly in response to the treatment (P < 0.05). The serum creatinine, blood urea, serum total protein, IgG, and complement C3 levels and urine erythrocyte counts were not significantly different (P > 0.05) from the respective pre-treatment values. The enrolled patients did not experience any drug reactions.
conclusionsThe combination of telitacicept and the standard treatment showed good clinical effects in children with IgAVN. This treatment showed good safety and had good tolerance.
Indexed as
Identifiers
40042623What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.